Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/43140
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLandi, A-
dc.contributor.authorMorici, N-
dc.contributor.authorVRANCKX, Pascal-
dc.contributor.authorFrigoli, E-
dc.contributor.authorBonacchini, L-
dc.contributor.authorOmazzi, B-
dc.contributor.authorTresoldi, M-
dc.contributor.authorCamponovo, C-
dc.contributor.authorMoccetti, T-
dc.contributor.authorValgimigli, M-
dc.date.accessioned2024-06-13T12:21:12Z-
dc.date.available2024-06-13T12:21:12Z-
dc.date.issued2023-
dc.date.submitted2024-06-13T12:19:02Z-
dc.identifier.citationJOURNAL OF CARDIOVASCULAR MEDICINE, 24 (12) , p. 920 -930-
dc.identifier.urihttp://hdl.handle.net/1942/43140-
dc.description.abstractAn excessive inflammatory response and a hypercoagulable state are not infrequent in patients with coronavirus disease-2019 (COVID-19) and are associated with adverse clinical outcomes. However, the optimal treatment strategy for COVID-19 patients managed in the out-of-hospital setting is still uncertain.-
dc.language.isoen-
dc.publisherLIPPINCOTT WILLIAMS & WILKINS-
dc.rights2023 Italian Federation of Cardiology - I.F.C. All rights reserved.-
dc.subject.otheranticoagulant therapy-
dc.subject.otheranti-inflammatory therapy-
dc.subject.othercolchicine-
dc.subject.otherCOVID-19-
dc.subject.otheredoxaban-
dc.subject.otherSARS-CoV-2-
dc.titleEdoxaban and/or colchicine in outpatients with COVID-19: rationale and design of the CONVINCE trial-
dc.typeJournal Contribution-
dc.identifier.epage930-
dc.identifier.issue12-
dc.identifier.spage920-
dc.identifier.volume24-
local.bibliographicCitation.jcatA1-
local.publisher.placeTWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.2459/JCM.0000000000001556-
dc.identifier.pmid37942793-
dc.identifier.isi001102568100009-
local.provider.typeWeb of Science-
local.uhasselt.internationalyes-
item.contributorLandi, A-
item.contributorMorici, N-
item.contributorVRANCKX, Pascal-
item.contributorFrigoli, E-
item.contributorBonacchini, L-
item.contributorOmazzi, B-
item.contributorTresoldi, M-
item.contributorCamponovo, C-
item.contributorMoccetti, T-
item.contributorValgimigli, M-
item.accessRightsOpen Access-
item.fullcitationLandi, A; Morici, N; VRANCKX, Pascal; Frigoli, E; Bonacchini, L; Omazzi, B; Tresoldi, M; Camponovo, C; Moccetti, T & Valgimigli, M (2023) Edoxaban and/or colchicine in outpatients with COVID-19: rationale and design of the CONVINCE trial. In: JOURNAL OF CARDIOVASCULAR MEDICINE, 24 (12) , p. 920 -930.-
item.fulltextWith Fulltext-
crisitem.journal.issn1558-2027-
crisitem.journal.eissn1558-2035-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
bb.pdfPeer-reviewed author version1.05 MBAdobe PDFView/Open
Show simple item record

WEB OF SCIENCETM
Citations

1
checked on Jul 16, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.